New strategy in the fight against obesity and T2D

The treatment of obesity and type 2 diabetes is increasingly shifting to newer incretin drugs, including GLP1 receptor agonists (single agonists such as semaglutide) and GIP- and GLP1-RA (dual agonists such as tirzepatide). However, there is still a need for stronger and more selective therapies with a better effect and minimized side effect profile. In the mouse model, the quintuple agonist GLP1:GIP:PanPPAR shows promise.